Growth potential High growth medical imaging startup targeting fatty liver disease with Velacur real-time AI guided liver stiffness and attenuation measurements, suggesting strong upsell opportunities to clinics expanding NAFLD/NASH screening programs.

Affordability advantage Low upfront cost positioning coupled with real-time AI guidance positions Velacur as an attractive entry point for smaller practices and regional labs looking to expand point-of-care liver imaging capabilities.

Clinical validation Multi-center data presentations at EASL and recognition as a Company to Watch bolster credibility; leverage clinical data discussions to engage hospital systems and independent labs seeking validated liver assessment tools.

Strategic partnerships Pilot AI usability enhancements with INOVAIT and ongoing product development indicate openness to collaboration; target academic centers, medtech distributors, and health IT integrators for co-development and distribution.

Executive traction Recent leadership changes and governance updates (new CEO and Board Chair) alongside a revenue base under 10M and $11M funding suggest momentum; approach growth-focused buyers and investors with scalable deployment plans and ROI narratives.